Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

BTK Inhibitors in CLL: Ibrutinib

July 30th 2020

Current Role for Chemoimmunotherapy in CLL

July 30th 2020

Treating CLL During COVID-19

July 30th 2020

Frontline Treatment Options in CLL

July 30th 2020

Selecting Frontline Therapy for CLL

July 30th 2020

COVID-19 and CLL Treatment Initiation

July 30th 2020

Selecting First-Line Therapy for CLL

July 30th 2020

Advances in Frontline Therapy for CLL

July 30th 2020

Impact of COVID-19 on Management of CLL

July 30th 2020

Initial Work-up for Chronic Lymphocytic Leukemia

July 30th 2020

Updated Data Confirm Long-Term Benefit With Tafasitamab/Lenalidomide in Relapsed/Refractory DLBCL

July 24th 2020

Tafasitamab plus lenalidomide followed by tafasitamab monotherapy was confirmed to induce durable responses and a clinically meaningful overall survival benefit in patients with relapsed/refractory diffuse large B-cell lymphoma.

Dr. Ghosh on Safety Results From the Phase 2 PILOT Trial in Non-Hodgkin Lymphoma

July 23rd 2020

Nilanjan Ghosh, MD, PhD, discusses the safety results from the phase 2 PILOT study with lisocabtagene maraleucel in non-Hodgkin lymphoma.

Selinexor Shows Meaningful, Durable Responses Linked With Improved OS in DLBCL

July 23rd 2020

Single-agent selinexor was found to induce durable responses with a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma who had received at least 2 prior lines of chemoimmunotherapy.

Fate Therapeutics Receives FDA Clearance of IND for FT819 in B-Cell Malignancies

July 22nd 2020

The FDA has cleared an investigational new drug application for the first-of-its-kind, off-the-shelf CAR T-cell product FT819, which targets CD19-positive malignancies.

Dr. Leslie on the Encouraging Evolving Treatment Landscape in MCL

July 21st 2020

Lori A. Leslie, MD, discusses the encouraging evolving treatment landscape in mantle cell lymphoma.

Dr. Burke on Current FDA Indications for BTK Inhibitors in B-Cell Malignancies

July 20th 2020

John M. Burke, MD, discusses current indications for BTK inhibitors in B-cell malignancies.

Ongoing Trial Evaluates Zanubrutinib in BTK-Intolerant B-Cell Malignancies

July 17th 2020

Ian W. Flinn, MD, PhD, discusses the adverse effects associated with BTK inhibitors in B-cell malignancies, as well as the design of an ongoing phase 2 study with zanubrutinib.

Novel Therapies: R2-GDP-GOTEL and Smart Start

July 17th 2020

Novel Treatment Combinations for R/R DLBCL

July 17th 2020

Relapsed/Refractory DLBCL: Unmet Needs

July 17th 2020